Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
Myriad Genetics (NASDAQ: MYGN) has announced a collaboration with Flatiron Health to integrate its MyRisk® Hereditary Cancer Test into Flatiron's OncoEMR® platform. This integration allows 4,200 providers at over 800 community-based cancer care locations across the U.S. to order, receive, and review MyRisk testing results directly through their daily EMR system. The partnership aims to streamline the workflow for germline testing, enhancing access to personalized patient care and reducing administrative burdens.
MyRisk is the first hereditary cancer test to be incorporated into Flatiron's OncoEMR. This collaboration is expected to simplify the ordering experience for clinicians and provide important health information to improve patient care and outcomes. Myriad Genetics plans to expand the availability of other genomic testing solutions on the OncoEMR platform in the future.
Myriad Genetics (NASDAQ: MYGN) ha annunciato una collaborazione con Flatiron Health per integrare il suo MyRisk® Hereditary Cancer Test nella piattaforma OncoEMR® di Flatiron. Questa integrazione consente a 4.200 fornitori in oltre 800 centri di cura oncologica negli Stati Uniti di ordinare, ricevere e rivedere i risultati del test MyRisk direttamente attraverso il loro sistema EMR quotidiano. L'obiettivo della partnership è semplificare il flusso di lavoro per i test germline, migliorando l'accesso alla cura personalizzata per i pazienti e riducendo i carichi amministrativi.
MyRisk è il primo test per il cancro ereditario ad essere integrato nell'OncoEMR di Flatiron. Si prevede che questa collaborazione semplifichi l'esperienza di ordinazione per i clinici e fornisca informazioni sanitarie importanti per migliorare la cura e i risultati per i pazienti. Myriad Genetics prevede di ampliare la disponibilità di altre soluzioni di test genomico sulla piattaforma OncoEMR in futuro.
Myriad Genetics (NASDAQ: MYGN) ha anunciado una colaboración con Flatiron Health para integrar su MyRisk® Hereditary Cancer Test en la plataforma OncoEMR® de Flatiron. Esta integración permite a 4,200 proveedores en más de 800 ubicaciones de atención oncológica comunitaria en EE.UU. ordenar, recibir y evaluar los resultados de las pruebas de MyRisk directamente a través de su sistema EMR diario. La asociación tiene como objetivo simplificar el flujo de trabajo para las pruebas de línea germinal, mejorando el acceso a una atención personalizada para los pacientes y reduciendo las cargas administrativas.
MyRisk es la primera prueba de cáncer hereditario que se incorpora al OncoEMR de Flatiron. Se espera que esta colaboración simplifique la experiencia de pedido para los clínicos y proporcione información de salud importante para mejorar la atención y los resultados de los pacientes. Myriad Genetics planea expandir la disponibilidad de otras soluciones de pruebas genómicas en la plataforma OncoEMR en el futuro.
Myriad Genetics (NASDAQ: MYGN)은 Flatiron Health와 협력하여 Flatiron의 OncoEMR® 플랫폼에 MyRisk® 유전성 암 검사를 통합한다고 발표했습니다. 이 통합을 통해 미국 전역의 4,200명의 제공자가 800개 이상의 지역 암 치료 센터에서 MyRisk 검사 결과를 직접 일상 EMR 시스템을 통해 주문하고, 수령하고, 검토할 수 있습니다. 이 파트너십의 목표는 유전자 검사에 대한 작업 흐름을 간소화하여 개인 맞춤형 환자 치료에 대한 접근성을 향상시키고 행정적 부담을 줄이는 것입니다.
MyRisk는 Flatiron의 OncoEMR에 통합된 첫 번째 유전성 암 검사입니다. 이 협력으로 임상의들의 주문 경험이 단순해지고, 환자 치료 및 결과를 개선하는 데 필요한 중요한 건강 정보를 제공할 것으로 기대됩니다. Myriad Genetics는 향후 OncoEMR 플랫폼에서 다른 유전체 검사 솔루션의 가용성을 확대할 계획입니다.
Myriad Genetics (NASDAQ: MYGN) a annoncé une collaboration avec Flatiron Health pour intégrer son MyRisk® Test de Cancer Héréditaire à la plateforme OncoEMR® de Flatiron. Cette intégration permet à 4 200 fournisseurs dans plus de 800 lieux de soins oncologiques communautaires aux États-Unis de commander, de recevoir et de consulter les résultats des tests MyRisk directement via leur système EMR quotidien. L'objectif de ce partenariat est de rationaliser le flux de travail pour les tests germinaux, d'améliorer l'accès aux soins individualisés pour les patients et de réduire les charges administratives.
MyRisk est le premier test de cancer héréditaire à être intégré à l'OncoEMR de Flatiron. Cette collaboration devrait simplifier l'expérience de commande pour les cliniciens et fournir des informations de santé importantes pour améliorer les soins aux patients et les résultats. Myriad Genetics prévoit d'élargir la disponibilité d'autres solutions de tests génomiques sur la plateforme OncoEMR à l'avenir.
Myriad Genetics (NASDAQ: MYGN) hat eine Zusammenarbeit mit Flatiron Health angekündigt, um den MyRisk® hereditären Krebstest in die OncoEMR®-Plattform von Flatiron zu integrieren. Diese Integration ermöglicht es 4.200 Anbietern an über 800 standortbasierten Krebsbehandlungszentren in den USA, MyRisk-Test Ergebnisse direkt über ihr tägliches EMR-System zu bestellen, zu erhalten und zu überprüfen. Das Ziel der Partnerschaft ist es, den Arbeitsablauf für Keimbahnuntersuchungen zu optimieren, den Zugang zu personalisierter Patientenversorgung zu verbessern und administrative Belastungen zu verringern.
MyRisk ist der erste hereditäre Kanzer-Test, der in das OncoEMR von Flatiron integriert wird. Man erwartet, dass diese Zusammenarbeit die Bestellerfahrung für Klinikärzte vereinfacht und wichtige Gesundheitsinformationen zur Verbesserung der Patientenversorgung und -ergebnisse bereitstellt. Myriad Genetics plant, die Verfügbarkeit anderer genomischer Testlösungen auf der OncoEMR-Plattform in Zukunft zu erweitern.
- Integration of MyRisk® Hereditary Cancer Test into Flatiron's OncoEMR® platform, potentially increasing test adoption
- Access to 4,200 providers at over 800 community-based cancer care locations across the U.S.
- Streamlined workflow for germline testing, potentially reducing administrative burdens and improving turnaround times
- Potential for increased revenue through wider adoption of MyRisk test
- Plans to expand availability of other genomic testing solutions on the OncoEMR platform
- None.
Insights
This collaboration between Myriad Genetics and Flatiron Health represents a significant advancement in integrating genetic testing into oncology practice. The incorporation of Myriad's MyRisk® Hereditary Cancer Test into Flatiron's OncoEMR® platform has several key implications:
- Improved accessibility: The integration allows 4,200 providers across 800+ cancer care locations to easily order and access genetic test results.
- Streamlined workflow: By embedding the testing process within the EMR, it reduces administrative burden and potentially improves turnaround times.
- Enhanced personalized care: Easier access to genetic information at the point of care facilitates more tailored treatment decisions.
- Market expansion: This partnership exposes Myriad's testing services to a broader network of oncology practices, potentially increasing test volumes.
While the immediate financial impact may be gradual, this integration positions Myriad Genetics favorably in the competitive genetic testing market, potentially driving long-term growth in test utilization and revenue.
Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR®
SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a leading health tech company dedicated to expanding the possibilities of point of care solutions in oncology. This collaboration allows physicians to order Myriad’s MyRisk® Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR®. MyRisk is the first hereditary cancer test to be incorporated into Flatiron’s OncoEMR.
The integration allows 4,200 providers at over 800 community-based cancer care locations across the U.S. in Flatiron’s network to conveniently order, receive, and review MyRisk testing results directly through their daily OncoEMR system. By creating a streamlined, end-to-end workflow for germline testing in OncoEMR, clinicians have access to the results they need at point-of-care, facilitating personalized treatment decisions for patients while reducing administrative burdens and improving turnaround times for results.
“Our collaboration with Flatiron integrates MyRisk testing with practicing clinicians’ current workflows, potentially enhancing access to and usability of germline testing for more personalized patient care,” said George Daneker Jr, MD, President and Chief Clinical Officer of Oncology, Myriad Genetics. “By making germline testing interoperable with OncoEMR, we aim to simplify the ordering experience for clinicians in Flatiron’s extensive network and provide important health information that may help improve patient care and outcomes. We look forward to expanding the availability of our other genomic testing solutions onto the OncoEMR platform in the future, addressing the needs of even more patients.”
“As we continue to advance personalized medicine, the importance of germline testing at the point of care is critical to improving patient outcomes,” said Stephen Speicher, MD, Senior Medical Director, Head of Clinical Oncology and Patient Safety at Flatiron Health. “By giving physicians the ability to order Myriad’s MyRisk Hereditary Cancer Test and to view the results directly within OncoEMR, we're offering clinicians a seamless way to access the information they need to practice precision medicine, facilitating better patient outcomes, more time with patients, and a better care experience for physicians and their patients.”
The integration is available now to all OncoEMR users.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to how the company’s collaboration with Flatiron may facilitate personalized treatment decisions for patients while reducing administrative burdens and improving turnaround times for results and how by making germline testing interoperable with OncoEMR, the company aims to simplify the ordering experience for clinicians in Flatiron’s extensive network and provide important health information that may help improve patient care and outcomes. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Myriad Genetics Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Myriad Genetics Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
Flatiron Health Media Contact
Nina Toor
press@flatiron.com
FAQ
What is the collaboration between Myriad Genetics (MYGN) and Flatiron Health?
How many providers can access Myriad Genetics' (MYGN) MyRisk test through Flatiron's OncoEMR?
What are the benefits of integrating Myriad Genetics' (MYGN) MyRisk test into Flatiron's OncoEMR?
Is Myriad Genetics (MYGN) planning to integrate other tests into Flatiron's OncoEMR platform?
